modelAnidulafungin
Extends from Pharmacolibrary.Drugs.ATC.J.J02AX06.
Information
| name: | Anidulafungin | |
| ATC code: | J02AX06 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 30.2 | L |
| clearance: | 1.1 | L/h |
| other parameters in model implementation | ||
Anidulafungin is an echinocandin antifungal used for the treatment of invasive candidiasis and other serious fungal infections. It inhibits glucan synthesis, a crucial component of fungal cell walls. It is approved for use in many countries, including the US and Europe.
Pharmacokinetics
Pharmacokinetic parameters observed in adult patients (both sexes) with invasive candidiasis after intravenous infusion.
References
Wasmann, RE, et al., & Brüggemann, RJ (2018). Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. Antimicrobial agents and chemotherapy 62(7) –. DOI:10.1128/AAC.00063-18 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29712664
Liu, P, et al., & Damle, B (2013). Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Antimicrobial agents and chemotherapy 57(4) 1672–1676. DOI:10.1128/AAC.02139-12 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23335738
Xie, R, et al., & Liu, P (2020). Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis. Clinical pharmacology and therapeutics 108(2) 316–325. DOI:10.1002/cpt.1831 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32189334
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)